Clinical Trial Update: Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Sacituzumab Govitecan in patients with metastatic urothelial carcinoma that cannot be removed or has spread; the study is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Gilead Sciences | Conditions: Metastatic Urothelial Cancer | Phase 2 | Status: RECRUITING